ruxolitinib

FDA Drug Profile — JAKAFI XR, JAKAFI, OPZELURA

ruxolitinib is listed in the FDA National Drug Code directory with 27 NDC codes, marketed under brand names including JAKAFI XR, JAKAFI, OPZELURA. Available dosage forms: tablet, extended release, tablet, cream.

Drug details

Generic Name
ruxolitinib
Brand Names
JAKAFI XR, JAKAFI, OPZELURA
Application Number
NDA217180
Sponsor
Incyte Corporation
NDC Codes
27
Dosage Forms
TABLET, EXTENDED RELEASE, TABLET, CREAM
Routes
ORAL, TOPICAL
Active Ingredients
RUXOLITINIB, RUXOLITINIB PHOSPHATE

Indications and Usage

1 INDICATIONS AND USAGE JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ( 1.1 ) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ( 1.2 ) steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ( 1.3 ) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. ( 1.4 ) 1.1 Myelofibrosis JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults. 1.2 Polycythemia Vera JAKAFI/JAKAFI XR is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea. 1.3 Acute Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older. 1.4 Chronic Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.